Adaptive Biotechnologies Corp’s recent filing unveils that its CEO and Chairman ROBINS CHAD M unloaded Company’s shares for reported $1.57 million on Feb 19 ’25. In the deal valued at $8.46 per share,186,080 shares were sold. As a result of this transaction, ROBINS CHAD M now holds 2,576,701 shares worth roughly $21.7 million.
Then, ROBINS CHAD M sold 99,107 shares, generating $836,463 in total proceeds. Upon selling the shares at $8.44, the CEO and Chairman now owns 2,576,701 shares.
Before that, Chad Robins bought 99,107 shares. Adaptive Biotechnologies Corp shares valued at $829,526 were divested by the Officer at a price of $8.37 per share.
A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in early January with a ‘”a Sector outperform”‘ rating. Piper Sandler also remained covering ADPT and has increased its forecast on December 21, 2022 with a “an Overweight” recommendation from previously “Neutral” rating. Credit Suisse started covering the stock on August 25, 2022. It rated ADPT as “an Underperform”.
Price Performance Review of ADPT
On Friday, Adaptive Biotechnologies Corp [NASDAQ:ADPT] saw its stock jump 1.81% to $8.42. Over the last five days, the stock has gained 1.08%. Adaptive Biotechnologies Corp shares have risen nearly 40.45% since the year began. Nevertheless, the stocks have risen 120.42% over the past one year. While a 52-week high of $8.95 was reached on 02/18/25, a 52-week low of $2.28 was recorded on 01/02/25. SMA at 50 days reached $7.20, while 200 days put it at $5.13.
Levels Of Support And Resistance For ADPT Stock
The 24-hour chart illustrates a support level at 8.13, which if violated will result in even more drops to 7.83. On the upside, there is a resistance level at 8.62. A further resistance level may holdings at 8.82. The Relative Strength Index (RSI) on the 14-day chart is 60.90, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.28, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 26.77%. Stochastics %K at 69.19% indicates the stock is a holding.
The most recent change occurred on June 03, 2022 when Piper Sandler began covering the stock and recommended ‘”a Neutral”‘ rating along with a $7.50 price target.
